Efficacy and safety of duloxetine for osteoarthritis: a comparator-stratified systematic review and meta-analysis
EClinicalMedicine · 29 Oct 2026
† Impact is the editorial-priority score. All scores are out of 100. Clinical is a stored clinical-importance score from the earlier method; it has not been recalculated.
Why it matters
Duloxetine is a guideline-listed option for osteoarthritis pain, and students should know that its benefit is small, best shown against placebo, and comes with more side effects.
The evidence
This meta-analysis pooled 20 randomised trials (21 comparisons, 3455 adults, mostly with knee osteoarthritis) testing duloxetine, an SNRI antidepressant, against placebo, active pain drugs such as NSAIDs or pregabalin, or as an add-on to other treatments. Overall, duloxetine modestly reduced WOMAC pain (standardised mean difference -0.36, 95% CI -0.58 to -0.14) and improved physical function (SMD -0.41), but it caused more adverse events (risk ratio 1.36). The clearest benefit came from placebo-controlled trials, while it did not clearly beat active drugs and add-on results were inconclusive.
A coherent primary effect estimate is unavailable. Clinical relevance does not estimate treatment benefit.
Why this rigour score?
Meta-analysis of RCTsDesign starting point: 60.8
Raised the score
- Placebo or sham control+5.1
- Prospectively registered+5.1
Lowered the score
No negative adjustments recorded.
Score capped at 64. A critical methodological failure for a review.
Methods at a glance
Recorded assessment- Comprehensive literature searchMet
- Risk of bias assessedMet
- Bias considered in synthesisMet
- Publication bias assessedMet
- Study exclusions justifiedNot met
- Prospective registrationMet
Not reported does not mean not done. Checks have different weights; this is not a count of boxes ticked.
See the full score breakdown
- Study design starting point
- 60.8
- Placebo or sham control
- +5.1
- Prospectively registered
- +5.1
- Pools randomised trials
- +5.1
- Comprehensive literature search
- +3.4
- Risk of bias assessed in the included studies
- +3.4
- Risk of bias carried into the synthesis
- +2.5
- Publication bias assessed
- +2.5
- Methodological cap
- −24
- Final rigour score rounded
- 64 / 100
Study design sets the starting point and a ceiling of 96. Recorded methods then adjust the score. Points are shown to one decimal place; the final score uses unrounded values.
Checklist from the stored appraisal. “Not met” describes the recorded criterion; it does not always produce a deduction. This overview supports reading the full study.
For journal club
1.For a patient with knee osteoarthritis who cannot take NSAIDs because of kidney disease or GI bleeding risk, how would you counsel them about the expected benefit and side effects of duloxetine?
2.Should coexisting depression or anxiety, or a centrally sensitised pain pattern, make you more likely to offer duloxetine to a patient with osteoarthritis, and how would you judge whether it is working at follow-up?
Original publication title
Efficacy and safety of duloxetine for osteoarthritis: a comparator-stratified systematic review and meta-analysis